Back to Newsroom
Back to Newsroom

Verizon Communications completes takeover of Verizon Wireless; Marvell Tech sinks despite good earnings

Monday, 24 February 2014 12:10 AM

Topic:

Verizon Communications Inc. (NYSE: VZ) – For an in-depth report on Verizon Communications Inc. follow: www.BullTrends.com/stockquote/VZ

Shares of Verizon Communications closed down 1.77% on Friday with a little over 60 million shares traded. The stock was one of the most active stocks in the NYSE. The company announced that it has completed its $130 billion deal to take over all of Verizon Wireless. Verizon Communications Inc. has said that owning all of its wireless unit would give it greater flexibility to invest in new technologies.

Marvell Technology Group Ltd. (NASDAQ: MRVL) – For an in-depth report on Marvell Technology Group Ltd. follow: www.BullTrends.com/stockquote/MRVL

Marvell Technology closed down 3.26% this past Friday on about 11.4 million shares traded. Before retracing the stock hit a new 52-week high of $16.62 during intra-day trading after the company reported fourth-quarter fiscal 2014 adjusted earnings (including stock-based compensation but excluding amortization, acquisition, restructuring and legal related expenses) of 22 cents per share which beat the Zacks Consensus Estimate of 18 cents per share. On a year-over-year basis, earnings per share soared 72.1% primarily due to higher revenues and operating margin expansion.

BioElectronics Corporation (OTC: BIEL) – For an in-depth report on BioElectronics Corporation follow: www.BullTrends.com/stockquote/BIEL

BioElectronics shares exploded this past Friday closing up 460%. The stock was one of the biggest gainers in the OTC market and traded over a billion shares. The maker of disposable drug-free healing pain therapy devices revealed the FDA recommendations announced in their Docket No. FDA-2012-N-0378, "Physical Medicine Devices; Reclassification and Renaming of Shortwave Diathermy for All Other Uses." "We are pleased that the FDA is reclassifying this technology to reflect its safety and efficacy," said Andrew J. Whelan, President, BioElectronics.  The FDA's recommendation makes scientific evidence the determinant for additional market clearances."

Juniper Networks, Inc. (NYSE: JNPR) – For an in-depth report on Juniper Networks, Inc. follow: www.BullTrends.com/stockquote/JNPR

Shares of Juniper Networks Inc. closed up 1.97% this past Friday on about 17.5 million shares traded. The stock was one of the most active stocks trading on the NYSE, almost doubling its average in trading volume. The company announced last week that it has reached a deal with hedge fund Elliott Management that will have the activist fund support the company's operating plan through 2015 in exchange for two seats on its board.  Juniper also announced a plan to cut $160 million in costs from its business by the first quarter of 2015 and target operating margins of 25% in that time span.

 

Wondering what your next move should be in the market? BullTrends.com can help lead the way. For free access to our complete stock reports, take a few minutes to register with us by clicking this link: http://www.bulltrends.com/

 

Disclosure: BullTrends.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.

Topic:
Back to newsroom
Back to Newsroom
Share by: